Prelude Therapeutics Incorporated

NASDAQ:PRLD

Biotechnology

Healthcare
$3.30 -3.22%

-$0.14 today

Market cap
$191.00M
Beta
1.01
P/E (TTM)
-4.5
EPS (TTM)
-$0.94
52W Low $0.75High $5.54

Volume 0.23M

Average 0.38M

PRLD EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Prelude Therapeutics IncorporatedNASDAQ: PRLD

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$9.99M, compared with -$31.65M a year earlier. Trailing-twelve-month EBITDA was -$76.13M.

Context

  • EBITDA amounted to 805.5% of revenue in FY2025, down 985.9 pp from a year earlier.
  • EBITDA grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 2 analysts of -$41.7M (+57.4%) for the fiscal year ending Dec 2026, a step up from the +22.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$9.99M+37.7% QoQ
Last fiscal yearDec 2025
-$97.79M+22.0% YoY
LTMMar 2026
-$76.13M+39.6% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+68.4%+38.3%-30.1 pp
1 year+22.0%+57.4%+35.3 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(97.79M) USD
Year-over-year change
+22.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How PRLD compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +39.6% is the 2nd highest of 11, against a peer median of +13.9%.
  • EBITDA amounts to 455.3% of revenue for PRLD, versus a peer median of 773.7%.
PRLD Competitors
EBITDA for PRLD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026-$45.49M USD-75.7%——
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026-$46.56M USD+46.6%—67.3%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026-$52.72M USD+20.1%—161.1%
IMRXImmuneering CorporationLTM Mar 2026-$58.85M USD+7.0%——
FHTXFoghorn Therapeutics Inc.LTM Mar 2026-$72.53M USD+7.7%—257.0%
TNYATenaya Therapeutics, Inc.LTM Mar 2026-$75.47M USD+22.0%—33540.9%
PYXSPyxis Oncology, Inc.LTM Mar 2026-$75.93M USD+0.5%—547.9%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026-$76.13M USD+39.6%—455.3%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-$84.35M USD-214.9%—142957.6%
CRBUCaribou Biosciences, Inc.LTM Mar 2026-$111.97M USD+23.4%—999.5%
IVAInventiva S.A.FY2025-€128.15M EUR+23.0%—2858.6%
Peer median (excluding PRLD) —+13.9%—773.7%

Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0007M12.14M
Cost of Revenue00001.71M
Gross Profit0007M10.43M
Gross Margin———100.0%85.9%
Research & Development86.78M92.89M103.39M118M94.3M
Selling, General & Admin26.96M30.65M28.88M28.72M22.41M
Operating Expenses113.74M123.54M132.28M146.71M115M
Depreciation & Amortization915K1.32M1.17M1.77M1.71M
EBITDA(110.78M)(114.11M)(120.66M)(125.4M)(97.79M)
EBITDA Margin———-1791.4%-805.5%
Operating Income(113.74M)(123.54M)(132.28M)(139.71M)(104.57M)
Operating Margin———-1995.9%-861.3%
Interest Income00000
Interest Expense00000
Other Income / Expenses2.04M8.1M10.44M12.54M5.07M
Income Before Tax(111.69M)(115.44M)(121.83M)(127.17M)(99.5M)
Pre-Tax Margin———-1816.8%-819.6%
Income Tax Expense00000
Net Income(111.69M)(115.44M)(121.83M)(127.17M)(99.5M)
Net Margin———-1816.8%-819.6%
EPS (Basic)(2.33)(2.27)(2.02)(1.68)(1.29)
EPS (Diluted)(2.33)(2.27)(2.02)(1.68)(1.29)
Weighted Avg Shares47.6M47.37M60.36M75.81M76.96M
Weighted Avg Shares (Diluted)47.6M47.37M60.36M75.81M76.96M

Prelude Therapeutics Incorporated

NASDAQ:PRLD

Intrinsic Alpha fair value

Locked

Current Price

$3.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.